

Pregnancy-associated plasma protein A (PAPP-A) as a mortality predictor of long-term hemodialysis patients



M. Kalousová, H. Benáková, A. A. Kuběna, S- Dusilová-Sulková, V. Tesař, T. Zima

Charles University, 1st Faculty of Medicine and General University Hospital, Prague, Czech Republic



Patients with chronic kidney disease

- High mortality rate mainly due to cardiovascular complications
- They differ from the general population
- Classical risk factors as well as non-traditional/uremia-related ones are involved

PAPP-A

pregnancy-associated plasma protein A

- metalloproteinase, cleaves IGFBP-4 → IGF-1 increase
- screening of Down syndrome in the 1st trimester
- present in ruptured atherosclerotic plaques
- biomarker of acute coronary syndrome
- increased in HD patients, related to renal function

Aim of the study

PAPP-A and related parameters

- other pregnancy protein – placental growth factor – **PIGF**
- matrix metalloproteinases – **MMP-2** and **MMP-9**
- molecules linked to PAPP-A action – **IGFBP-4** and **IGF-1**
- established cardiac markers – **cTnI**, **BNP**
- inflammatory markers – **CRP**; **retinol**

→ relationship of their serum levels to prognosis of long term hemodialysis patients in 5-years follow-up

Study design:

Prospective observational cohort study.

261 long-term hemodialysis patients

- follow-up for 5 years (11/2003-11/2008)
- patients from 6 HD centres in the Czech Republic
- 141 men and 120 women, mean age 64±13 years
- clinical and laboratory characteristics collected at the beginning of the study

66 healthy controls

- 25 men and 41 women, mean age 59±9 years

Clinical characteristics of hemodialysis patients

- | | |
|-------------------------------|----------------|
| • duration of HD treatment | median 2 years |
| • diabetes mellitus | 33% |
| • dyslipidemia | 41% |
| • hypertension | 84% |
| • cardiovascular disease | 61% |
| • cerebrovascular disease | 24% |
| • peripheral vascular disease | 25% |

Acknowledgement

- physicians and nurses from co-operating dialysis centres
Dr. Kratochvilová and Dr. Hodková (Prague)
Dr. Gorun (Ústí nad Orlicí)
Dr. Hobzek and Mrs. Žďánská (Písek)
Dr. Suchanová and Dr. Křížová (Tábor)
Dr. Nýdlová (Strakonice)

- laboratory staff
Dr. Soukupová and Mrs. Hudcová

- patients and controls

The study was supported by grant IGA MH CZ NS/10043-4/2008 and by the research project MSM 0021620807.

Basic laboratory parameters

Parameter	HD patients	Controls	p HD vs. controls
Hemoglobin (g/L)	106±13.2	141±10.1	<0.001
Creatinine (μmol/L)	753±198	88±13	<0.001
Albumin (g/L)	37.8±3.8	44.4±2.6	<0.001
CRP (mg/L)	10.0±16.5	3.3±2.4	0.002
Leukocytes (x10 ⁹ /L)	6.92±1.95	6.41±1.70	0.1
BMI (kg/m ²)	25.4±4.52	25.5±3.42	0.9

Follow up of HD patients - 5 years

- + 146 patients (56%)
 - 71 - cardiovascular cause
 - 42 - infection
 - 14 - tumour
 - 15 - other cause
- 52 patients – transplantation, 8 of them +
- 2 patients censored to due other reason

Laboratory methods

- **PAPP-A** – TRACE (KRYPTOR, Brahms)
- **PIGF**, **IGFBP-4**, **MMP-2** and **MMP-9** – ELISA (RD Systems)
- **IGF-1** – IRMA
- **BNP** and **cTnI** – CLIA
- **Retinol** – HPLC
- Basic nutritional and inflammatory parameters - standard methods, automated analyzers

Statistical analysis

- software **SPSS v.16.0**
- **Survival analysis**
 - Kaplan-Meier analysis
 - Cox regression – univariate and multivariate analysis (forward and backward methods)
- overall mortality, cardiovascular mortality, mortality due to infection
- transplantation taken as time dependent covariate
- BCH parameters treated as continuous variables
- HR (95%CI) expressed per SD, for age per year

Conclusion


This study demonstrates PAPP-A as an independent predictor of overall mortality and mortality due to infection in hemodialysis patients. Our results suggest superior relationship of PAPP-A to infection-inflammation than to cardiovascular risk in HD patients.

Results: PAPP-A

- 27.6±15.5 mIU/L in HD vs. 9.4±2.5 mIU/L in controls, p<0.001
- Significant independent predictor
 - for overall mortality
HR/SD (95%CI) 1.237 (1.060-1.444), p=0.007
 - for mortality due to infection
HR/SD (95%CI) 1.416 (1.115-1.798), p=0.004
 - not for cardiovascular mortality

Overall mortality

PAPP-A below and over 30.8 mIU/L (upper quartile), p=0.03



Other markers and mortality all increased in HD except for MMP-9

- **PIGF** – n.s. (p=0.08-0.1)
- **MMP-2** and **MMP-9** – n.s.
- **IGFBP-4** – n.s.
- **IGF-1** – significant in uni-variate analysis
- **cTnI** – significant in both uni-variate and multi-variate analysis for overall and cardiovascular mortality
- **BNP** - significant only in uni-variate analysis for overall and cardiovascular mortality
- **Retinol** - significant in both uni-variate and multi-variate analysis for overall and cardiovascular mortality (Kalousová et al. Am J Kidney Dis 2010)

Significant Independent Mortality Predictors for Overall, Cardiovascular and due to Infection Mortality

	Overall mortality HR (95% CI)	p	Cardiovascular mortality HR (95% CI)	p	Mortality due to infection HR (95% CI)	p
PAPP-A	1.237 (1.060-1.444)	0.007			1.416 (1.115-1.798)	0.004
cTnI	1.411 (1.200-1.658)	<0.001	1.470 (1.208-1.790)	<0.001		
Albumin	0.722 (0.595-0.876)	<0.001	0.588 (0.447-0.774)	<0.001		
Creatinine	0.789 (0.637-0.978)	0.03			0.672 (0.487-0.926)	0.02
Retinol	0.775 (0.632-0.950)	0.01	0.671 (0.500-0.902)	0.008		
Parathormone					0.621 (0.364-1.058)	0.08
Age	1.030 (1.011-1.048)	0.001				
Diabetes mellitus	1.625 (1.128-2.340)	0.009			2.966 (1.474-5.966)	0.002
CVD	1.638 (1.039-2.582)	0.03	3.753 (1.699-8.289)	0.001		
Transplantation			0.121 (0.016-0.893)	0.04		